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Abstract: Ever since the first studies, restoring proteinase imbalance in the lung has traditionally
been considered as the main goal of alpha1 antitrypsin (AAT) replacement therapy. This strategy was
therefore based on ensuring biochemical efficacy, identifying a protection threshold, and evaluating
different dosage regimens. Subsequently, the publication of the results of the main clinical trials
showing a decrease in the progression of pulmonary emphysema has led to a debate over a possible
change in the main objective of treatment, from biochemical efficacy to clinical efficacy in terms of lung
densitometry deterioration prevention. This new paradigm has produced a series controversies and
unanswered questions which face clinicians managing AAT deficiency. In this review, the concepts
that led to the approval of AAT replacement therapy are reviewed and discussed under a new
prism of achieving clinical efficacy, with the reduction of lung deterioration as the main objective.
Here, we propose the use of current knowledge and clinical experience to face existing challenges
in different clinical scenarios, in order to help clinicians in decision-making, increase interest in the
disease, and stimulate research in this field.
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1. Introduction
Alpha1 antitrypsin deficiency (AATD) is a rare genetic condition that determines the appearance
of pulmonary emphysema and liver damage in its severe forms [1]. As a rare condition, the available
evidence indicating how to proceed in different clinical situations that may occur is limited and not
always clear-cut. Therefore, controversies and doubts may arise about the management of different
aspects of this condition in daily clinical practice. This is particularly evident when it comes to
considering exogenous alpha1 antitrypsin (AAT) replacement therapy, which is also known as
augmentation therapy, for severely deficient patients. Different aspects including indications, the dose
regimen for dose intervals, or the differences between the presentations available are still a matter
for debate. Interestingly, in recent years, there have been some advances that have clarified, at least
in part, some of the previous controversies in relation to this therapy. One major finding is the
ability of AAT augmentation therapy to decrease emphysema progression as measured by lung
densitometry [2–4]. Consequently, the preservation of pulmonary density with exogenous AAT has
sparked a debate over a potential change in the main aims of treatment from biochemical efficacy
to clinical efficacy, based on emphysema progression evaluated by lung densitometry. Under this
new paradigm, clinicians managing AATD are faced with a number of controversies and unanswered
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questions. In this work, we propose harnessing current knowledge and clinical experience to find
answers to the current debate, with a view to helping clinicians to take key decisions, arouse interest in
the disease, and foster research in this field.
2. Initial Assumptions
2.1. Biochemical Efficacy
Plasma AAT normally diffuses through the endothelial barrier into the interstitium. Here, most of
the AAT flows out through the lymphatic vessels; however, part of the diffuse AAT passes through the
epithelial barrier into the alveolar epithelial lining fluid (Figure 1). Accordingly, the amount of serum
AAT is directly proportional to the amount of AAT that migrates to the interstitium and the epithelial
lining fluid of the lungs [5]. As a result, the initial trials on AAT replacement therapy were focused on
demonstrating that this therapy could restore the AAT levels and anti-elastase activity in the epithelial
lining fluid. This aim is referred to as biochemical efficacy.
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Figure 1. Diagram indicating alpha1 antitrypsin in plasma from normal individuals diffusing across 
the alveolar capillary endothelial barrier into the interstitium. AAT, Alpha1 antitrypsin; ELF, 
epithelial lining fluid. The sizes of the vascular, interstitial, and alveolar compartments are not to 
scale, for educational purposes. 
However, four figures obtained from five patients (Figure 2) in 1981 [6] were enough to start a 
path that would culminate in the approval of the Food and Drug Administration in 1987. This initial 
study demonstrated that, by administering intravenous exogenous AAT in seven-day infusion 
periods, exogenous AAT could reach the epithelial lining fluid, increase the protein concentration at 
this compartment, and improve the anti-elastase activity [7]. A subsequent study in a few patients 
also confirmed that, by administering AAT infusions every seven days, serum levels of AAT were 
kept above a level defined as a protective threshold (discussed below) [8]. 
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confirmed that, by administering AAT infusions every seven days, serum levels of AAT were kept
above a level defined as a protective threshold (discussed below) [8].J. Clin. Med. 2020, 9, x FOR PEER REVIEW 3 of 21 
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replacement therapy with 4.0 g of AAT. (D) Lower respiratory tract neutrophil elastase inhibitory
activity following weekly intravenous infusions of 4.0 g of AAT.
Finally, A T replacement therapy was approved f r i tra e s i f si ase on bioche ical
efficacy and preliminary safety data. herefore, it is i portant to re e ber that, at those times,
augmentation therapy for T as an exa ple of a treat ent that had been approved for use in
patients, without being evaluated for efficacy and safety in cohorts of patients through traditional
clinical trials in clinical, functional, or radiological terms.
2.2. Protective Threshold Level
A so-called protective threshold lev l has been defined as the amount of AAT in serum fro which
there is no increased risk of devel ping em hyse a. Notably, this limit was not based on specific
patient data but on epidemiological data, following the description of the presence of emphysema in
the initial cases [8]. Interestingly, this threshold level was first described by radial immunodiffusion,
which suggests that that AAT levels ≤50 mg/dL are associated with a high risk for the development of
emphysema, levels between 50 and 80 mg/dL confer an uncertain risk, and levels >80 mg/dL confer no
increase in risk above the background risk [8]. Therefore, 80 mg/dL by radial immunodiffusion was
the initial accepted limit.
However, there is a considerable confusion regarding this level. In those days, commercially
available standards yielded values for amounts of AAT that were identified as higher than the
true values [8]. Therefore, the result had to be adjusted depending on which standard was
used—the commercially available standard or a true laboratory standard. To differentiate the procedures,
initial studies expressed values as milligrams per deciliter when based on the commercial standard,
and as micromolar units when based on the true laboratory standard. According to these different units,
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80 mg/dL with the commercial standard corresponded to 11.2 µM with the true laboratory standard [8].
Later, in another study, 80 mg/dL by radial immunodiffusion corresponded to 10.9µM [9]. Consequently,
in the ATS consensus, it was established that 80 mg/dL by radial immunodiffusion corresponded to
50 mg/dL by nephelometry, using commercially available standards, which in turn corresponded to
11 µM, using the American National Health Lung Blood Institute (NHLBI) standard [10]. Interestingly,
11 µM of the NHLBI standard corresponds to 57.2 mg/dL by nephelometry. Therefore, these two values
of 11 µM and 57.2 mg/dL by nephelometry, using the NHBLI standard, have been interchangeably
identified as the protective threshold.
Interestingly, what this protective threshold really shows is a level from which emphysema
associated with the deficit is more likely to appear, based on epidemiological studies. However,
we really have no idea if this is the limit above which the progression of emphysema is slowed
down with replacement therapy, as the concept of “protective threshold” would imply. Accordingly,
we still do not know the threshold which identifies the optimal therapeutic response in terms of
emphysema progression [11], and so, rather than “protective threshold”, it would be better to call it
“detection threshold” or “severity threshold” or “risk threshold”.
2.3. Dose
Since AAT half-life in healthy MM individuals is reported to be from 3.8 to 5.2 days (mean 4.6,
standard error of the mean 0.21) [12], the initial trials devised an infusion schedule that would allow
once-weekly administrations for PiZ individuals, thus maintaining serum AAT levels above the
considered protective level (as discussed above). Weekly infusions containing around 4.0 g of AAT
were therefore prepared from 3.5–4.0 L of pooled plasma [6]. This dose corresponds to 57.1 mg/kg for
a subject of 70 kg. Accordingly, the subsequent trial used the standard dose of 60 mg/kg in weekly
infusions [8], which has been maintained until now.
2.4. Route of Administration
Since the first studies, the administration of AAT has been intravenous [6–8]. This route of
administration is the only one available to this day. Inhaled AAT administration has been tried in
recent years, but it is still under exploration [13].
2.5. Origin of AAT
From the beginning, the AAT has been obtained from fresh plasma from human donors. Specifically,
the first studies reported that between 3 and 4 L of pooled human plasma was necessary to obtain
4 gr of AAT for administration [6]. Alternative ways of obtaining AAT were investigated in the
early years, in particular from recombinant DNA in microorganisms [14] or from recombinant AAT
associated with virus vectors as a potential tool for the gene therapy [15], cell lines producing AAT [16],
silkworm larvae [17], or a plant-made recombinant AAT from Nicotiana benthamiana, a close relative
of the tobacco plant which is indigenous to Australia [17]. All of these are exploratory possibilities,
but, currently, AAT continues to be obtained from human plasma.
2.6. Final Statement
Starting from the uncertain origins commented above, replacement treatment with exogenous
AAT obtained from human plasma, at a dose of 60 mg/kg in weekly intravenous administrations, is the
maintenance therapy for severe AATD, with the objective of achieving biochemical efficacy by aiming
for serum levels of AAT above 11 µM, using the NHBLI standard.
3. Clinical Efficacy: A Change of Paradigm
It was only from the late 1990s onward when longitudinal data on the impact of AAT
replacement therapy started to become available. This information comes mainly from seven
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major observational studies (Table 1), and mostly from two major cohorts, namely the German
scientific working group for the therapy of lung diseases (WALT from the German abbreviation:
Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen) [18–20] and the
American NHBLI registry for individuals with severe deficiency of AAT [21,22], together with other
studies in the USA [23] and Spain [24]. Additionally, three clinical trials plus one pooled analysis
of two of these trials explored the clinical impact of AAT augmentation therapy [2–4,25] (Table 1).
To cut a long story short, although observational trials reported several significant results favoring
augmentation therapy in terms of exacerbations, lung function, or survival, the main finding from the
formal clinical trials was a reduction in the loss of lung density by lung densitometry. This finding
was relevant since it implied that, by administering intravenous exogenous AAT, not only are we able
to regain biochemical efficacy, but the treatment also achieves a change in the natural progression of
emphysema, with a potential longer-term prognostic impact [26,27]. Therefore, augmentation therapy
has the potential to modify the natural progression of AATD-associated emphysema.
As a main consequence, the objective of exogenous administration of AAT is to be modified from
seeking biochemical efficacy to seeking clinical impact in the form of prevention of lung deterioration
and emphysema progression. However, this change in therapeutic objective poses a dilemma. If the
goal of treatment is no longer to ensure biochemical efficacy but to slow the progression of emphysema,
this opens up a number of controversies and unanswered questions as regards when the therapy is
indicated and its administration and follow-up, which are discussed hereafter.
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Table 1. Description of the population included in the main studies with augmentation therapy.
Study N
Age FEV1 Mutations
Eligibility Criteria Cohort Results * Eligibility Criteria Cohort Result * Eligibility Criteria Cohort Result
Observational studies with control
Seersholm N, et al.; WALT.
Eur Respir J, 1997 [18] 295 NR 46 (8)
FEV1 < 65% or decline
> 120 mL/year 37 (14)% Severe AATD (NR) NR
NHLBI Registry. AJRCCM,
1998 [21] 927 ≥18 years 46 (11) NR
<35%: 43.6%
35–49%: 21.1%
50–79%: 16.2%
≥80%: 19.1%
AAT ≤ 11 µM or ZZ NR
Wencker M, et al.; WALT.
Eur Respir J, 1998 [19] 443 >18 years 45 (7)
FEV1 < 65% or decline
> 120 mL/year
Ex-smokers: 35.5 (14.8)%
Non-smokers: 42.2 (18.2)%
AAT < 50 mg/dL
(nephelometry)
AAT < 80 mg/dL
(immunodiffusion)
ZZ: 88.9%
SZ: 7.1%
Other/unknown: 4.0%
Wencker M, et al.; WALT.
Chest, 2001 [20] 96 NR 44 (8)
FEV1 < 65% or decline
> 120 mL/year 41 (17.3)% AAT < 35%
ZZ: 85%
SZ: 8%
Other: 3%
Stoller JK, et al.; NHLBI.
Chest, 2003 [22] 747 NR 48 (9) NR 37 (18)%
AAT ≤ 11 µM or ZZ
or null NR
Tonelli AR, et al. Int J
COPD, 2009 [23] 164 NR 61.3 (0.7) NR 43 (2)% ZZ ZZ
Barros-Tizón JC, et al. Ther
Adv Respir Dis, 2012 [24] 127 >18 years 51.7 (9.1) NR 1.25 (0.50) L
AAT ≤ 11 µM (50
mg/dL) and ZZ. rare
or null
ZZ: 93.6%
SZ: 0.8%
Other: 5.6%
Clinical trials
Dirksen A, et al.;
Danish–Dutch study.
AJRCCM, 1999 [3]
56 NR Danish: 50.4 (1.62)Dutch 45.1 (1.17)
FEV1
30–80%
Danish: 1.5 (0.9) L
Dutch: 1.6 (0.1) L ZZ ZZ
Dirksen A, et al.; EXACTLE.
Eur Respir J, 2009 [2] 77 ≥18 years 54.7 (8.4) NR 46.3 (19.6)% AAT ≤ 11 µM ZZ or Zn
Chapman KR, et al.; RAPID.
Lancet, 2015 [4] 180 18–65 53.8 (6.9)
FEV1
35–70% 47.4 (12.1)% AAT ≤ 11 µM
ZZ: 93%
Other: 7%
* Numerical data expressed as mean (standard deviation). FEV1: forced expiratory volume in 1 s (expressed as absolute values in liters or as percentage of the theoretical value the patient
should have according to its age, gender, height, weight, and race). NR, not reported; AAT, alpha1 antitrypsin ; AATD, Alpha1 antitrypsin deficiency; NHLBI, National Health Lung Blood
Institute; COPD, chronic obstructive pulmonary disease; WALT, from the German abbreviation: Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen; AJRCCM,
American Journal of Respiratory and Critical Care Medicine
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4. Controversies over Indication
4.1. Age Limits
The eligibility criteria regarding age are not very explicit in all trials. When available, these are
adult studies (>18 years), and the average age is around 45 to 50 years (Table 1). Although there may
be extreme values in the distributions, there is little information on very young or very old cases.
Although cases in children requiring augmentation therapy have been described anecdotally [28],
being young is not normally an issue from a clinical perspective, since by the time emphysema develops,
patients are already young adults [29,30]. The issue comes with elderly cases. Currently, there is no
information on the impact of AAT augmentation therapy in this cohort. These patients are clearly
disease survivors, and the dilemma of initiating a life-long weekly intravenous treatment over the
age of 70 or 80 is controversial. In these cases, despite the fact that we could restore AAT anti-elastase
activity, achieving the biochemical efficacy, it is not well established how much further the emphysema
may progress and what window of opportunity is available to have an impact on long-term lung
density deterioration in these elderly patients. Therefore, therapy ought to be individualized and must
be agreed with the patient and the caregivers, since many comorbidities and social circumstances may
influence this decision. In any case, family screening should be carried out in these cases, to detect
severe cases amongst younger relatives. Fortunately, current technologies facilitate these diagnostic
procedures in the population [31,32].
4.2. Mutations
AATD is a co-dominant autosomal inherited genetic disease caused by mutations in the SERPINA1
gene on chromosome 14. Mutations are named with a letter from A to Z, according to the migration
speed in the isoelectric focusing gel. The normal M allele has an average migration rate. The two
most frequent mutated alleles are S and the more severe Z. As shown in Table 1, most studies include
ZZ and rare or null allele carriers, with only a minority with SZ or other less frequent mutations.
Interestingly, in these trials, the eligibility criteria focused on having a severe AATD (identified by
an AAT value below the protective threshold), irrespective of the mutation. Although we can restore
the biochemical efficacy of the approved dose for all mutations, the impact on emphysema progression
has been shown for those with AAT ≤ 11 µM, which included ZZ, Zn, and other unspecified severe
mutations. Accordingly, the drug′s technical specifications for augmentation therapy states that the
indication is for PiZZ, PiZ (null), Pi (null) (null), and PiSZ. However, in the main study showing a clear
impact on lung density, the RAPID trial [4], there were only 12 cases (7%) with severe mutations other
than ZZ, which were two SZ, one Z/Null, and nine other non-specified mutations. Unfortunately,
these mutations were not evaluated separately and there is no sensitivity analysis evaluating this in
the trial. As a result, when aiming at biochemical efficacy, it is reasonable to consider treatment in
those with severe deficits (AAT ≤ 11 µM), regardless of the associated mutation. However, the exact
impact on the decline of lung densitometry in non-ZZ patients needs to be clarified in the future.
4.3. Lung Function Limits
The evaluation of lung function impairment in chronic obstructive pulmonary disease (COPD) is
performed with FEV1. Consequently, the limits of lung function impairment in previous studies was
evaluated by this parameter (Table 1). Additionally to the potential relevance of AAT in COPD [33],
according to these studies, there were two ways of evaluating FEV1 as the baseline value or as the
yearly decline. Although the majority of the cases had an FEV1 below 50%, the included patients
presented a wide variability in this spirometric value. Interestingly, the main trial evaluating AAT
augmentation therapy on densitometry, the RAPID trial, included patients with FEV1 between 35 and
70% [4]. In fact, the technical specifications for Prolastin include a formal indication of FEV1 limits
from 35 to 60%. This has led to the question about whether milder or more severe cases should receive
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augmentation therapy to impact on emphysema progression. There are two points worth considering
about this issue.
First, despite this formal lack of evidence, common sense and clinical experience urge us to
indicate or not to stop augmentation therapy below an FEV1 of 35%. The clinical practice guidelines
from the Alpha1 Foundation clearly state that intravenous augmentation therapy is recommended
for individuals with a predicted FEV1 less than 30%, and, for those with an FEV1 greater than 65%,
they recommend discussing with each individual the potential benefits of reducing lung function
decline, considering the cost of the therapy and lack of evidence for its benefits [34]. Similarly,
the Portuguese guidelines state that augmentation therapy should not be discontinued in case of
pulmonary function deterioration, even if it reaches the lowest established limit for its initiation [35].
Second, despite the well-known role of FEV1 in COPD, we know that FEV1 is a poor surrogate
measure for emphysema. Notably, gas transfer is reduced much earlier than FEV1 [36,37], and it is
therefore a more sensitive marker of disease onset. Additionally, gas transfer keeps worsening in the
final stages of the disease, whereas FEV1 decline slows down [38], thus making it also a more sensitive
marker of disease deterioration than FEV1 [36]. Finally, during disease progression, gas transfer
is a better marker of emphysema progression than FEV1. Altogether, gas transfer may be a more
sensitive and specific test of emphysema development than FEV1. However, the indication for
augmentation therapy continues to be established according to FEV1 values instead of diffusing
capacity. Thus, if emphysema is the goal of treatment rather than biochemical efficacy, it would
probably be desirable to use diffusing capacity instead of FEV1 as the basis for indication for therapy
and as a monitoring and follow-up parameter. If this is the case, we should consider the FEV1 debate
to be over and turn our focus to the functional parameters with a closer relationship to emphysema.
4.4. Indication in Liver Disease
Despite the potential clinical importance of AATD-associated liver failure, the available treatments
are still at the very early stages of clinical development. Currently, liver transplantation remains the
definitive option for its treatment [39]. However, according to the current records, AATD is a rare cause
of liver transplantation [40]. Some treatments are beginning to be evaluated, such as glibenclamide
analogs [41], ursodeoxycholic acid homologues [42], or RNA-targeted treatments [43]. In this context,
AAT augmentation therapy has not been explored as a potential treatment for AATD-associated
liver condition until very recently. Interestingly, a recent collaborative study between Sweden and
Germany reported that exogenous AAT lowered SERPINA1 expression in primary human hepatocytes
in a dose-dependent manner [44] (Figure 3). Consequently, if the reproducibility and clinical relevance
of these findings are confirmed, a possible new indication is opened as a treatment for the prevention
of liver involvement that should be prospectively evaluated in trials with patients at risk of developing
this complication.
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of biochemical efficacy, it seems that administrations every three and every four weeks would be 
insufficient to keep the trough pre-dose value (Cmin) above the considered protection threshold (as 
discussed above) [45]. For this reason, it is recommended to use the usual weekly dose, which, in 
some cases, can be changed to a biweekly administration with double doses, since this regimen has 
also been shown to be appropriate [46] and safe [47]. However, if we include in the equation the 
objective of slowing down the progression of emphysema instead of achieving biochemical efficacy, 
the scenario changes considerably. Interestingly, the so-called Danish–Dutch study, the first study to 
evaluate the role of replacement therapy in lung density, used a dose of 250 mg/kg every four weeks, 
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Figure 3. Purified A1AT reduces SERPINA1 expression in a dose-dependent manner in primary human
hepatocytes. Exogenously added purified AAT reduced SERPINA1 expression in primary human
hepatocytes isolated from both proficient and deficient liver tissue. The reduction was more prominent
following Oncostatin M (OSM 10 ng/mL) stimulation, known to increase expression of SERPINA1.
*, P < 0.05; **, P < 0.001; ***, P < 0.001; ****, P < 0.0001). © 2017 Karadagi, et al. This is an open-access
article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and
source are credited. Obtained from Reference [44].
5. Controversies in the Administration
5.1. Infusion Frequency
As discussed above, the weekly frequency of AAT infusions was based on the half-life of this protein
and the biochemical efficacy of the first preparations. However, in our search for more comfortable
dosages, other alternatives have been tried by doubling, tripling, and even quadrupling the dose and
the administration interval to up to 240 mg/kg every four weeks. From the point of view of biochemical
efficacy, it seems that administrations every three and every four weeks would be insufficient to keep
the trough pre-dose value (Cmin) above the considered protection threshold (as discussed above) [45].
For this reason, it is recommended to use the usual weekly dose, which, in some cases, can be
changed to a biweekly administration with double doses, since this regimen has also been shown to be
appropriate [46] and safe [47]. However, if we include in the equation the objective of slowing down the
progression of emphysema instead of achieving biochemical efficacy, the scenario changes considerably.
Interestingly, the so-called Danish–Dutch study, the first study to evaluate the role of replacement
therapy in lung density, used a dose of 250 mg/kg every four weeks, resulting in an improvement in the
progression of emphysema [3]. Unfortunately, the study of lung density was an exploratory objective
in which the densitometric technique was not standardized. Consequently, it would be desirable to
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replicate the study with the current lung densitometry methodology. Interestingly, the result of the
Danish–Dutch study opens up another question about how it is possible that administration every
four weeks does not maintain biochemical efficacy during the four weeks [45] but does have an effect
on lung densitometry [3]. This paradox highlights the discrepancy between biochemical and clinical
efficacy, which should be explored in future trials. Additionally, it supports the idea mentioned above
that the so-called “protective threshold” is a misnomer and should rather be known as “the risk
threshold for developing emphysema”.
5.2. Correct Dose
As discussed above, the weekly dose of 60 mg/kg was established following the experience of
the first researchers, and it has remained to this day, since it ensured biochemical efficacy. However,
the RAPID trial identified that lung density decrease rate was related with the median serum AAT
concentration, so that the higher the serum concentration, the higher impact on lung density decline
prevention. This data also suggested that there was no ceiling effect with the data provided by the
RAPID trial [4], implying that achieving higher serum level might have a greater impact on lung
density decline. This hypothesis has been recently explored in the SPARK study, which evaluated
the safety and pharmacokinetic profile of weekly infusions of a 120 mg/kg dose and showed that
this dose is safe and well-tolerated and provides more favorable physiologic AAT serum levels [48].
SPARTA (Study of ProlAstin-C Randomized Therapy with Alpha-1 augmentation), an ongoing
randomized, placebo-controlled trial is currently assessing the efficacy and safety of 120 mg/kg
administered weekly over three years [11]. The recruitment for this trial is now over, and the results,
once available, will have to be evaluated to complete this discussion between the discrepancy between
biochemical and clinical efficacy.
5.3. Differences between Preparations
Augmentation therapy with AAT has undergone extensive pharmacological development since
the first approval of Prolastin in 1987 (Figure 4). All the preparations can be divided into three types:
lyophilized preparations (Prolastin and other country-specific brand names, Trypsone, Alfalastin,
and Aralast, originally named Respitin), lyophilized concentrated preparations (Zemaira in the
USA—known as Respreeza in Europe—Prolastin C, and Aralast NP), and finally the preparations with
a liquid presentation (Prolastin C liquid and Glassia). From a biochemical efficacy perspective, all of
these gained approval by comparing their clinical efficacy with either Prolastin, as the first approved
presentation, or Prolastin C (pivotal studies showing biochemical efficacy are depicted in Figure 5).
However, if the aim of the treatment is to decrease loss of lung density rather than biochemical
efficacy, then only three of these products have been evaluated in clinical trials, namely Alfalastin in the
Danish–Dutch study [3], Prolastin in the EXACTLE (EXAcerbations and Computed Tomography scan
as Lung End-points) trial [2], and Zemaira/Respreeza in the RAPID trial [4]. Nevertheless, neither the
standard methodology of lung densitometry nor the approved explored dose was followed in the
Danish–Dutch study. Therefore, it would be of interest to compare the differences between Prolastin
and Zemaira/Respreeza in trials.
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To begin with, there are certain differences between these two presentations [49]. First, it has been
reported in biochemical comparisons between both that Zemaira/Respreeza shows a better profile
in terms of total protein content, AAT potency, specific AAT activity, and purity [50,51]. Secondly,
the concentration of AAT is different in both preparations with Zemaira/Respreeza having a higher
concentration (Table 2). Thirdly, the results of the clinical trials are probably not directly comparable
due to the different population and study design (Table 2). Therefore, until the possible emergence of
new therapeutic options, augmentative treatment with AAT is the only specific treatment for patients
with congenital emphysema, and both products have demonstrated their efficacy in slowing the
progression of emphysema (Table 2). Accordingly, this treatment should be available for patients
who meet internationally established criteria and are controlled and supervised by reference health
centers [49]. Unfortunately, we will probably not be able to directly explore these differences further,
since future trials are being planned with lyophilized concentrated or liquid preparations.
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Table 2. Differences between Prolastin and Zemaira/Respreeza.
Prolastin Zemaira/Respreeza
Origin * Human donor plasma Human donor plasma
Presentations * 1 gr + 40 mL solvent (25 mg/mL)
1 gr + 20 mL solvent (50 mg/mL)
4 gr + 76 mL solvent (50 mg/mL)
5 gr + 95 mL solvent (50 mg/mL)
Excipients *
Powder:
Sodium chloride
Sodium dihydrogen phosphate
Solvent: Water for injections
Powder:
Sodium chloride
Sodium dihydrogen phosphate
monohydrate
Mannitol
Solvent: Water for injections
Purity (AAT/proteins) [49] 76.9% 97.4%
Specific activity (active AAT/proteins) [49] 64% 86.2%
Infusion velocity * 0.08 mL/kg/min 0.08 mL/kg/min
Time of infusion 60 mg/kg dose † 30 min 15 min
Time of infusion 120 mg/kg dose ‡ 60 min 30 min
Lung density decline reduction [4,25] Versus basal: −1.73 g/L/yearVersus placebo: 1.01 g/L/year
Versus basal: −1.45 g/L/year
Versus placebo: 0.74 g/L/year
*, Obtained from the technical leaflet; †, At a dose of 60 mg/kg/wk for a 75 kg patient; ‡, At a dose of 120 mg/kg/2 wk
for a 75 kg patient.
6. Controversies in the Follow-Up
6.1. Monitoring Control in the First Few Months
Due to the current controversy over dosage therapy and replacement therapy, once indicated,
the next question is how to establish the suitable dose. From the perspective of biochemical efficacy,
the debate is about the use of Cmin during the initial administration as a way of identifying which
patients can receive biweekly infusions. Here, some authors warn against systematic measurements
of Cmin [52], whereas others suggest there is scope for an individualized dosage regimen for AAT
augmentation therapy [53]. Interestingly, if we are aiming for individualized biochemical efficacy,
it follows that measuring Cmin during the first infusions is the only way to identify how patients
respond to other regimens than weekly administrations. Once established, there is no further need to
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evaluate it. However, if we are aiming to achieve clinical efficacy in terms of preventing lung density
decline progression, we will have to admit that further information is needed. We have the results
of the Danish–Dutch study, which quadrupled the dose and the administration interval and showed
a significant impact on the outcome (with the limitations mentioned above) [3], despite biochemical
efficacy not being guaranteed [45]. Additionally, the really interesting measure would be the evaluation
of the progression of emphysema by lung densitometry. Unfortunately, the methodology used in the
RAPID trial for lung density evaluation is not available for clinical practice. Alternatively, other forms
of evaluation emphysema progression should be evaluated in the future to identify lung function
or radiological parameters that allow us to identify the correct dose for emphysema progression
prevention in the follow-up.
6.2. Discontinuation of Augmentation Therapy
The impact of discontinuation of augmentative treatment has not been a major topic of debate in
recent years until the recent publication of two letters. McElvaney, et al. [54] recently reported on the
consequences of abrupt cessation of AAT replacement therapy, showing an increase in the frequency of
exacerbations over a 77-day period, with two deaths due to exacerbation (Figure 6), accompanied by
increased circulating levels of inflammatory biomarkers. Recently, another study [55] described
post-transplant complications leading to reduced survival only in patients who had discontinued
replacement therapy a few weeks before transplant. Interestingly, the effect seemed to have faded
by 11 months, suggesting a possible role of the timing of the withdrawal of replacement therapy.
These authors [55] hypothesized about a transient inflammatory rebound phenomenon short after
withdrawal of therapy. Interestingly, the study by McElvaney, et al. [54] describes this increase in the
inflammatory load during the weeks after withdrawal, which seems to peak at three months (Figure 6).
The progression of the inflammatory markers and the clinical consequences beyond that point should
be explored, to define the window of risk, since two behaviors could potentially be seen thereafter
(Figure 6). As a result, these two letters have opened up new questions about the repercussion of
abrupt cessation of augmentation therapy that should be further explored. Very recently the role of
AAT as a modulator of the neutrophil membrane has been described, providing new data on the role
of neutrophil-associated AATD disease [56].
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6.3. Pulmonary Transplantation
The relationship between augmentation therapy and lung transplantation has sparked another
major controversy. Beyond the debate on the survival benefits of lung transplantation in AATD [57–59],
the issue at hand now is the role of augmentation therapy in the peritransplantation. At this point,
the debate is largely mediated by the decision over whether to continue replacement therapy after
transplantation, with two conflicting opinions with their own arguments (Table 3). On the one hand,
augmentation therapy has been shown to have several potential benefits. First, intravenous AAT
inhibits elastase mediated injury to the transplanted lung in humans [60]. Second, animal models have
shown that the administration of human AAT before reperfusion in recipients improved immediate
post-transplant lung function [61]. Third, AAT attenuates acute lung allograft injury [62]. On the other
hand, as expected, augmentation therapy retains its biochemical efficacy in the recipient, although we
do not know about the potential preventive effect of augmentation therapy on newly developed
emphysema in the transplanted lung. With the available information, this decision is especially
relevant, in the light of the study by Kleinerova, et al. [55] mentioned above, in which the authors
suggested that discontinuation of augmentation therapy should be undertaken several months before
lung transplantation, to avoid an increased risk of complications. Therefore, either augmentation
therapy is stopped just at inclusion in the lung-transplant waiting list or is maintained non-stop during
the complete process. Trials are needed to clarify this confusing situation.
Table 3. Arguments for and against maintaining augmentation therapy after lung transplant.
In Favor Against
The biochemical efficacy is expected to be the
same as in non-transplanted AATD patients.
There are no formal trials on its clinical efficacy in lung
density deterioration after transplant.
Augmentation therapy is safe and
well-tolerated, and patients get used to it as part
of their lives. It is not expected to create an
additional burden.
Lung transplant patients already have to cope with
a considerable amount of medication with potential
adverse effects that determine their lives, without adding
another treatment of unproven efficacy in this context.
AATD lung-transplant patients are generally
younger, with a longer life expectancy, so it is
vital to take all the necessary measures to
protect the transplanted lung.
Emphysema due to AATD is a slow, progressive disease.
It may take decades until clinically relevant emphysema
is developed in the new lung.
The number of lung donors is limited, so every
transplant has an opportunity cost, since it
could have been received by another patient.
Therefore, it is unethical not to take all possible
steps to preserve the transplanted lung.
It has not been proven that the risk of rejection is
increased if recipients do not receive
augmentation therapy.
7. The Future: A Second Change of Paradigm Coming
Despite the fact that the diagnostic approach to AATD currently varies between different health
institutions and countries [63], diagnosis currently begins with the determination of AAT levels in blood
as the main form of screening for the disease. Although this approach is probably the most suitable at the
moment, it leaves us with some unknowns. It has been reported a variable disease penetrance of AATD,
with different patients with the same mutations suffering different degrees of disease burden. Of note,
AAT levels do not clarify why some patients develop severe lung disease, while others do not carry the
same mutation [64,65]. In this context, the potential role of evaluating anti-elastase activity could be of
help. Anti-elastase activity is one of the main markers in the importance of a specific mutation [66].
Beyond serum AAT levels, anti-elastase activity is also influenced by external and environmental factors
like alcohol intake [67] or active smoking [68], as well as by inorganic compounds [69] and inflammatory
processes [70]. In human-immunodeficiency virus patients, AAT levels increased in bronchoalveolar
lavage fluid and blood. However, anti-elastase activity decreased in bronchoalveolar lavage from
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human-immunodeficiency virus patients, suggesting impaired AAT function [71]. Accordingly, it has
been described that there is a disagreement between protein concentration in peripheral blood with
anti-elastase activity [72]. Finally, to complicate things further, a mutation has been described which
is secreted at normal levels in cellular models of AATD but with a severe reduction in anti-elastase
activity, therefore identifying the first pure functionally deficient AATD mutation [73].
Consequently, we may need to address the debate about the adequacy of basing AATD screening
exclusively on the peripheral blood concentration of AAT or if it is possible to determine anti-elastase
activity as a complementary marker of lung involvement in AATD [74,75]. Beyond making general
recommendations for a healthy lifestyle, which is also necessary, anti-elastase activity should probably
be measured to provide a clearer idea of the potential penetration of the disease and enable us to
give more thorough patient-based diagnosis and information on the presence and importance of the
disease in specific cases in order to evaluate its impact on the long-term deterioration of lung density.
Here, multinational clinical research collaboration initiatives [76] will pave the way for acquiring more
thorough knowledge on AATD that will result in a more personalized approach for these patients.
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